What is B. Riley's Estimate for ARWR FY2026 Earnings?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - Analysts at B. Riley raised their FY2026 earnings per share (EPS) estimates for shares of Arrowhead Pharmaceuticals in a research note issued on Tuesday, October 21st. B. Riley analyst M. El-Saadi now expects that the biotechnology company will post earnings per share of ($1.02) for the year, up from their previous forecast of ($3.16). B. Riley currently has a "Strong-Buy" rating on the stock. The consensus estimate for Arrowhead Pharmaceuticals' current full-year earnings is ($2.42) per share.

Several other research analysts have also commented on the stock. Royal Bank Of Canada dropped their price objective on shares of Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an "outperform" rating for the company in a research note on Friday, August 8th. Wall Street Zen downgraded shares of Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Friday, July 18th. HC Wainwright reiterated a "buy" rating and set a $80.00 price target on shares of Arrowhead Pharmaceuticals in a report on Wednesday, October 8th. TD Cowen upgraded Arrowhead Pharmaceuticals to a "strong-buy" rating in a report on Monday, July 28th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Arrowhead Pharmaceuticals in a report on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $43.14.

Arrowhead Pharmaceuticals Stock Down 0.7%

NASDAQ ARWR opened at $37.35 on Friday. The company has a quick ratio of 4.87, a current ratio of 4.87 and a debt-to-equity ratio of 0.39. The company has a fifty day moving average of $30.24 and a two-hundred day moving average of $20.46. The firm has a market capitalization of $5.16 billion, a price-to-earnings ratio of -29.18 and a beta of 1.13. Arrowhead Pharmaceuticals has a 52 week low of $9.57 and a 52 week high of $40.29.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.94) by ($0.32). The firm had revenue of $27.77 million during the quarter, compared to analyst estimates of $29.01 million. During the same period last year, the firm earned ($1.38) earnings per share.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. CWM LLC increased its stake in shares of Arrowhead Pharmaceuticals by 6.7% during the third quarter. CWM LLC now owns 12,179 shares of the biotechnology company's stock valued at $420,000 after buying an additional 764 shares during the period. Oak Ridge Investments LLC increased its stake in shares of Arrowhead Pharmaceuticals by 2.5% during the first quarter. Oak Ridge Investments LLC now owns 33,734 shares of the biotechnology company's stock valued at $430,000 after buying an additional 823 shares during the period. Resona Asset Management Co. Ltd. increased its stake in shares of Arrowhead Pharmaceuticals by 8.7% during the second quarter. Resona Asset Management Co. Ltd. now owns 11,218 shares of the biotechnology company's stock valued at $180,000 after buying an additional 900 shares during the period. Salomon & Ludwin LLC purchased a new position in shares of Arrowhead Pharmaceuticals during the third quarter valued at $34,000. Finally, Empowered Funds LLC raised its holdings in shares of Arrowhead Pharmaceuticals by 6.9% in the 1st quarter. Empowered Funds LLC now owns 15,252 shares of the biotechnology company's stock valued at $194,000 after purchasing an additional 979 shares in the last quarter. Institutional investors own 62.61% of the company's stock.

Insider Transactions at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, insider James C. Hamilton sold 20,000 shares of the business's stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $35.00, for a total value of $700,000.00. Following the completion of the sale, the insider directly owned 212,122 shares of the company's stock, valued at $7,424,270. The trade was a 8.62% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last three months, insiders have sold 60,000 shares of company stock valued at $1,725,000. 4.30% of the stock is owned by insiders.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.